1:48 PM
 | 
Apr 11, 2019
 |  BC Extra  |  Company News

Syncona gene therapy start-ups Gyroscope, Orbit merge

Syncona is merging portfolio companies Gyroscope and Orbit, which the U.K. firm says creates the first gene therapy company for retinal diseases that includes a clinical pipeline, an in-house manufacturing process and a delivery platform (see “Syncona Eyes a Matching Pair”).

Gyroscope Therapeutics Ltd. (Stevenage, U.K.) has a gene therapy for dry age-related macular degeneration (AMD) in Phase I/II testing and its own manufacturing capabilities. Syncona Ltd. (LSE:SYNC) launched Orbit Biomedical Ltd. (Amber, Pa.) last year to develop a subretinal surgical gene therapy delivery system. The combined company will retain Gyroscope’s name.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD